secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-124025
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics COO departs, named Senior Advisor in organizational realignment
--------------------------------------------------------------------------------

- Terry Dagnon ceased as Chief Operations Officer effective November 30, 2023.
- Appointed as Senior Advisor under company's strategic realignment for ONS-5010 priorities.
- Dagnon continues to receive current base salary and benefits under existing employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923124025/0001104659-23-124025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923124025/tm2332305d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer